EU Joint Clinical Assessment (JCA) in Rare Disease
EU Joint Clinical Assessment is no longer theoretical. The HTA Coordination Group’s 2025 Annual Report marks the[…]
EU JCA readiness: early signals for development teams
EU Joint Clinical Assessment (JCA) is still early in its implementation. Much of the formal framework is[…]
Why 2026 matters for EU Joint Clinical Assessment readiness
As we move into 2026, EU Joint Clinical Assessments (JCAs) are shifting from policy concept to operational[…]
Europe’s shift to patient evidence: what it means for JCA and rare-disease sponsors
What is changing in Europe’s approach to patient evidence? Recent guidance, including the EMA Reflection Paper on[…]